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Rising interest for probiotics in the recent years was caused by the possibility of their use 
in prevention and cure of different types of human and animal intestinal disorders. During 
20th century many research studies were concentrated on finding new types of probiotic 
cultures. In this work, for the production of probiotic yogurt, we used commercially 
available, new generation probiotic lactic yeast “Turval B0399”, produced by Italian 
company Turval Laboratories. Turval B0399 is the culture of yeast species Kluyveromyces 
marxianus fragilis B0399. This yeast is characterized by the unique ability of fermenting 
with the enzyme -galactosidase and by production of lactic acid, a fundamental substance 
in cell metabolic reactions. This probiotic yeast, naturally resistant to antibiotics, mitigate 
negative effects of antibiotics - by competitive colonisation of intestine it regulates 
intestinal dismicrobism by preventing the growth of pathogens, such as Candida albicans, 
while increasing the number of residential bifidobacterias. It keeps intestinal homeostasis, 
improves immunity (in in vitro studies it was shown to decrease the production of 
proinflammatory cytokines, while in studies on patients with atopic dermatitis it decreased 
the IgE level). It improves the general metabolism and is very successful in prevention and 
treatment of different intestinal disorders (Crohn's disease and Irritable Bowel syndrome). 
In this work we studied the growth of the yeast Kluyveromyces fragilis B0399 and its 
influence on the growth of the probiotic bacteria Lactobacillus acidofilus LA5 and 
Bifidobacterium lactis BB12 with the final aim of achieving the maximal number of live 
cells during the production of probiotic yogurt (>106 cfu/g). The experimental production 
of the probiotic yogurt with Turval B0399 was done in the Dairy Laboratory of the 
Department of Animal Science, Faculty of Agriculture, University of Novi Sad, while all 
microbiological analyses were done in JPS Dairy Institute, Novi Beograd. During the 
production of probiotic yogurt we followed the activity of the yeast Kluyveromyces fragilis 
B0399 in different concentrations – 0.5%; 1%; and 3% and under different fermentation 
temperatures - 39 C; 23,5 C and 4 C (in the cooled probiotic yogurt). 
Among all studied conditions we managed to obtain the sufficient number of live yeast 
cells in the final product when adding 1% of Turval product during the fermentation phase 
on 23,5 C, when the number of live cells is 3.5x107cfu/g probiotic bacteria and 3.6x105 
cfu/g Kluyveromyces fragilis B0399. Clinical studies have shown that in order to exhibit its 
probiotic functions the daily uptake of the yeast Kluyveromyces fragilis has to be 10 
millions of live cells (certified by the Italian Ministry of Health). 
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Sensor properties of this probiotic yogurt, odour, taste and colour, are preserved up to 
expiry date of 30 days. Final product is safe for use and has beneficial properties for good 
intestinal performance and general health of its consumers.  
Key words: Kluyveromyces marxianus, probiotic culture, Turval-B0399, yogurt 
 
Introduction 
Food industry companies have rather high expectations in food products that meet the 
consumers’ demand for a healthy life style. This especially addresses foods that are not 
intended only to satisfy hunger and provide humans with necessary nutrients, but also to 
prevent nutrition-related diseases and increase physical and mental wellbeing of 
consumers, so called “functional food” (Granato et al., 2010; Jankovic et al., 2010; Kaplan 
et al., 2014). One of the most promising areas for the development of functional foods lies 
in the modification of gastrointestinal tract activity by the utilization of beneficial microbes 
(probiotics) in diary products or other dietary supplements, which, when administrated in 
adequate amounts are aimed at promoting human health (Food and Agriculture 
Organization/World Health Organization (FAO/WHO), 2001; Jankovic et al., 2010). 
According to a new market report published by Transparency Market Research, 
“Probiotics Market: Global Industry Analysis, Market Size, Share, Trends, Analysis, 
Growth and Forecast”, the global probiotic market has been in constant growth, of 7.6% 
over the previous 5-year period, and is expected to reach  22 billion euros by 2015 
(Saxelin, 2008; Pedretti, 2012).  
Probiotics have a documented therapeutic role in reducing certain human illnesses, 
particularly gastrointestinal diseases, caused by deficient or compromised gut microflora 
(Allen et al., 2004; Canani et al., 2007; Enck et al., 2011); anti-cholesterol activity and 
anti-high blood pressure effect (Lye et al., 2009; Jahreis, 2002); alleviation of lactose 
intolerance symptoms by active lactose hydrolysis (Yoshida et al., 2010), promotion of 
beneficial immune responses (Leyer GJ et al., 2009); beneficial skin effects and reduction 
of allergies’ symptoms (Krutmann, 2009);  antimicrobial, anticarcinogenic and anti-
mutagenic activities (Orrhage et al., 1994; Rea et al., 2007). There are several proposed 
molecular mechanisms underlying these functions, including short-chain fatty acid (SCFA) 
production, the enhancement of the barrier function of the intestinal epithelium, the 
suppression of the growth and binding of pathogenic bacteria, and alterations of the 
immune activity of the host (Tuomola et al., 1999; Ventura et al., 2009; Aragon et al., 
2010). Furthermore, probiotics can alter colonic fermentation and stabilize symbiotic 
microbiota (Spiller, 2008), improving the dynamic interplay between the resident bacterial 
community and the host. 
Increasing evidence about the therapeutic potential of probiotics is substantiating constant 
research and selection of novel microbial species and strains with greater probiotic 
potential and better properties according to selection criteria (Havenaar et al., 1992), such 
as: total safety for the host, resistance to gastric acidity and pancreatic secretions, adhesion 
to epithelial cells, antimicrobial activity, inhibition of adhesion of pathogenic bacteria, 
evaluation of resistance to antibiotics, tolerance to food additives and stability in the food 
matrix. The probiotics used today have not been selected on the basis of all these criteria, 
but the most commonly used probiotics are specific strains of lactic acid bacteria (LAB), 
belonging mainly to the genus Bifidobacterium or Lactobacillus. Less frequently used 
organisms are strains of Propionibacterium freudenreichii, bacilli, or yeasts (Wassenaar 
and Klein, 2008). Kluyveromyces marxianus fragilis (found also as Kluyveromyces fragilis 
or Kluyveromyces marxianus) is lactic yeast isolated from different dairy products, mainly 
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kefir (Zhou et al., 2009; Bolla et al., 2011). The importance of this species in food 
development and fermentation is well documented, while its probiotic activities have been 
recently well recognized for one strain, named K. marxianus B0399, isolated from whey 
and curds of cow’s milk and deposited at the Belgian Coordinated Collection of 
Microorganisms (BCCM) (accession number MUCL 41579) by Turval Laboratories Italy. 
Well characterized, health-promoting, probiotic properties of this strain include: strong 
adhesion to mucosal surfaces and persistence in the intestine; capacity to finely tune the 
immune response by decreasing the production of the proinflammatory cytokines TNF- , 
IFN- , IL-6 and the chemokines IP-10 and IL-8 (known to play a crucial role in host 
defense mechanisms) in PBMCs and Caco-2 cells in the presence of inflammatory stimuli 
such as LPS, IL-1 , or enteropathogenic bacteria (Maccaferri et al., 2012a and 2012b ). 
Furthermore, two studies have independently proved that this yeast can improve the 
growth and survival of bifidobacteria in complex food matrices and proximal and 
transverse colon (Rada, 1997; Maccaferri et al., 2012). It is capable of survival during 
gastric transit, maintaining its vitality and fermentation capacity (Mustacchi et al., 2010). 
These scientific evidences are supporting the valuable therapeutic effects of this strain, 
seen in multiple clinical studies such as: Irritable Bowel Syndrome (Andreoli and 
Lovrovich 2009; Roda and Cornia 2009), Irritable Colon (Andreoli, 2006), candidiasis 
(Cettolo and Riul, 2006; Mustacchi et al., 2009), antibiotic-associated diarrhea (Vaughan, 
2002) etc. For all these reasons, K. marxianus B0399 is the active ingredient in different 
functional foods currently marketed in several countries worldwide and it is included in the 
European Food Safety Authority (European Food and Safety Authority (EFSA), 2010) list 
of qualified presumption of safety (QPS) biological agents added to food and feed (EFSA, 
2010). As such, this strain is of particular interest for the global functional food industry. 
Since the highest consumption of probiotic products in Europe is associated with probiotic 
yogurt (Wassenaar and Klein, 2008), our aim in this work was to optimize the production 
conditions of the new generation, yogurt-like, probiotic dairy beverage, containing mixed 
probiotic population: yeast Kluyveromyces fragilis B0399 and probiotic bacteria 
Lactobacillus acidofilus LA5 and Bifidobacterium lactis BB12. We studied the 
Kluyveromyces growth and its influence on the growth of the probiotic bacteria. The final 
aim was to achieve the maximal number of live cells upon the production of probiotic 
yogurt (>106 cfu/g) and after a desired, 30 day, storage period. Production process was 
further optimized to reach both the ‘therapeutic minimum’ of live Kluyveromyces B0399 
cells in the final product (> 8x104 cfu/g of 125g yogurt package or > 1x107 cfu/diem, 
indicated by the Italian Ministry of Health (Bottona et al., 2008)) as well as the lower cost 
of the production process, acceptable for the Serbian market. 
 
Materials and methods 
Milk 
Pasteurized and homogenized milk with 1.6% of milk fat was used for the production of 
fermented dairy beverages. Milk was taken from “Mlekara Dana”, Vrbas, and the quality 
of milk was in accordance with “The regulations on the quality of raw milk” (the Official 
Gazette of the RS 21/2009) and “The regulations on the quality of dairy products and 
starter cultures” (the Official Gazette of the RS, 33/2010 and 69/2010). 
Starter cultures 
Two different types of starter cultures were used for the production of the fermented, 
probiotic, dairy beverages. A classic probiotic yoghurt (commercial name) was produced 
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with mixed, ABY-6 starter culture (Chemibiotech s.r.l, Italy), which contains classical 
yogurt strains: containing Lactobacillus delbreukii subsp.bulgaricus and Streptococcus 
salivarius subsp.thermophiles, as well as two probiotic strains, Lactobacillus acidofilus 
LA5 and Bifidobacterium lactis BB12. In addition, the new generation probiotic product 
was produced using bacterial ABY-6 starter together with a non-conventional, semi-
processed, liquid yeast starter, TURVAL B0399® (Turval Laboratories, Udine, Italy). 
Turval B0399 starter contains probiotic lactic yeast strain K. marxianus B0399 in the 
concentration 1,4x107 yeast cells/ml. 
 Production of fermented dairy beverages 
Milk used for the production of probiotic beverages is low fat milk, standardized to 1.6% 
milk fat, homogenized and pasteurized initially at 72° for 20s, subjected to bio-chemical 
analysis of the milk quality, then additionally pasteurized at 92-96°C for 10 and cooled to 
the inoculation temperature. During the production of the new generation probiotic yogurt, 
yeast K. marxianus B0399 was inoculated in three different concentrations – 0.5%, 1% and 
3%, and under different fermentation temperatures – 39°C, 23.5°C and 4°C (in the cooled 
fermented product). Precisely, in 1000 ml of milk, cooled to a certain inoculation 
temperature, bacterial and yeast inoculum were added in three different ways as follows: 
A) alongside, both cultures were added to heated milk, at a temperature of 39°C; or B) 
alongside, both cultures were added to milk at room temperature (23.5°C); and C) 
separately, bacterial inoculum was added to heated milk, at a temperature of 39°C while 
yeast inoculum was added at the end of the fermentation process, in the cooled product 
(4°C), before mixer homogenization. 
In all cases fermentation was interrupted when the fermented product reached 4.75-4.65 
pH level and 32-36°SH, which means 4h for 39°C fermentation and about 24h for 23.5°C 
fermentation.  
Fruit containing, yogurt-like fermented milk products with probiotic properties were made 
in two ways: a) a classical ‘fruit containing probiotic yogurt’ was made by inoculating 
ABY-6 probiotic starter culture and 39°C while the new generation ‘fruit containing 
probiotic yogurt’ was made as previously described for B). In all cases, according to the 
manufacturer’s suggestion, 10% of fruit paste was added to the cold product (4°C) before 
mixer homogenization. Apart from 52% of blended strawberries, fruit paste contained 
small amount of sucrose, water, citric acid, colors and aromas.  
All previously mentioned products, containing K. marxianus B0399, were further 
optimized in order to achieve both the ‘therapeutic minimum’ of live yeast cells in the final 
product (  8x104 cfu/g for 125g yogurt package) and the lowest production cost. This 
optimization was done by varying the size of yeast inoculum form 3% to 0.5%.  
ABY-6 probiotic starter culture was added to achieve a concentration of 0.005% in 
manufacturing yogurt samples. 
Products were stored for 30 days in a fridge, at the temperature of 4-8ºC. 
Analysis of milk and fermented dairy products 
Chemical composition of milk was analyzed right before the yogurt production: 
-  dry matter was measured with direct method at the temperature of 102±1 ºC;  
-  milk fat was measured by the Gerber method; - total proteins by Kjeldahl method. 
Organoleptic (taste, smell, colour, consistency) and physicochemical analysis of all 
products were performed on the day 1 after production, and on the day 30 after production. 
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For this purpose standard methods of analysis were used: active acidity was measured with 
pH meter and titratable acidity was measured by Soxhlet-Henkel method.  
Microbiological analysis (probiotic bacteria and yeast count) was also performed at two 
previously mentioned time points (day 1 and day 30 after production). Sample suspensions 
and serial dilutions were prepared in accordance with the standards defined by ISO 6887-
5:2010 (Microbiology of food and animal feeding stuffs -- Preparation of test samples, 
initial suspension and decimal dilutions for microbiological examination -- Part 5: Specific 
rules for the preparation of milk and milk products). The number of live K. marxianus 
B0399 cells was determined by the colony count method according to the standards 
defined by ISO 21527-1:2008 (Microbiology of food and animal feeding stuffs -- 
Horizontal method for the enumeration of yeasts and moulds -- Part 1: Colony count 
technique in products with water activity greater than 0.95). Similarly, the number of 
probiotic bacteria, L. acidofilus LA5 and B. lactis BB12, was determined by colony-count 
technique described in ISO 20128:2006 and ISO 29981:2010 standards respectively (Milk 
products -- Enumeration of presumptive Lactobacillus acidophilus on a selective medium/ 
Enumeration of presumptive bifidobacteria -- Colony-count technique at 37 degrees C).  
 
Results and discussion 
Production of the innovative, plane, dairy probiotic beverage containing K. marxianus 
B0399 
Table 1 shows the ‘chemical composition of milk used for the production of probiotic 
beverages’.  
 















1.59 3.32 4.53 8.61 10.185 149 
 
Probiotic species in a specific probiotic food carrier should be alive to an adequate number 
in order to exert their positive effects on the health of the host. This attribute is known as 
‘viability’ or ‘therapeutic minimum’ in literature, defined by the adequate number of live 
probiotic cells in a food product at the time of consumption (Korbekandi, 2011). Various 
factors have been recognized to affect the viability of probiotic species during storage of 
fermented dairy products such as interaction between species present, culture, fermentation 
time and temperature, level of inoculation, carbohydrate source in the fermentation 
medium, final acidity, dissolved oxygen, and storage time and temperature (Korbekandi et 
al., 2011; Mohammadi and Mortazavian, 2011). While synergic growth-promoting effects 
between L.acidophilus and Bifidobacterium species are well documented (Kneifel et al., 
1993) there is no data in the literature about the co-inoculation effect of kefir-derived yeast 
K. marxianus on the survival of these two probiotic bacteria. We tested this effect by 
comparing the number of probiotic bacteria between two products: i) fermented product 
made by co-inoculation of ‘ABY6’ bacterial culture and ‘Turval’ yeast culture and ii) 
yogurt fermented with ABY6 only, where yeast culture was added at the end of the 
production process, in the cooled coagulum. While in the first product the milk is used as 
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the growth medium for both probiotic bacteria and yeast, in the later product it is the 
classical ‘probiotic yogurt’ that is used as a carrier for the innovative probiotic lactic yeast.  
Data in Table 2A (‘Maximising number of probiotic species by varying fermentation 
temperature’) show that the presence of the yeast strain K. marxianus B0399, when added 
post-fermentation, (in the cooled coagulum) does not significantly influence the final count 
of probiotic bacteria. The results in Table 2A also suggest that it is rather a long 
fermentation time (24h) at low temperature (23°C±1°C), which is beneficial for both 
bacterial, and yeast growth during the production process. This result is supported by the 
literature data that lower incubation temperature favours the growth of bifidobacteria 
(Kneifel et al., 1993), and it also shows that the room T was better choice for K. marxianus 
growth, while typical fermentation T of 39°C seemed to even negatively effect the number 
of K. marxianus cells in the final product. This result is in agreement with the multi year 
fermentation practice of kefir products containing K. marxianus strain (Nambou et al., 
2014). 
 
Table 2A. Maximising number of probiotic species by varying fermentation temperature 
Probiotic culture 

















ABY-6 culture 39°C 7h / 8.1 x106 / 
ABY-6 culture + 3% 
Turval 39°C 7h / 7x10
6 2x105
ABY-6 culture 39°C 7h 3% Turval 7.5 x106 3.75 x105
ABY-6 culture + 3% 
Turval 23.5°C 24h / 9.4x10
6 9.5 x105
 
Table 2B. Maximising number of yeast cells by varying inoculum size of Turval B0399 
Probiotic culture 

















ABY-6 culture + 1% 
Turval 39°C 7h / 7.5x10
6 4.8x104
ABY-6 culture 39°C 7h 1% Turval 7.1x106 9x104
ABY-6 culture + 
1% Turval 23.5°C 24h / 3.5x10
7 3.6x105
ABY-6 culture + 
0.5% Turval 23.5°C 24h / 1.9x10
7 2.8x105
 
After we identified the ideal fermentation conditions for our mixed microbial population 
we tested whether it was possible to decrease the yeast inoculum size with respect to the 
initial 3% concentration and thus decrease the production cost of the new probiotic 
product. The 3% inoculum size is the Turval concentration that should be applied when the 
product is made by adding Turval in the cooled coagulum (4°C) in order to satisfy the 
‘therapeutic minimum’ at the time of the consumption (  1x107 live yeast cells/diem) 
(Bottona et al., 2008). We hypothesized that by co-inoculating 1% or even 0.5% of yeast 
culture under favourable fermentation conditions (24h at room temperature) we could still 
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obtain the Kluyveromyces ‘therapeutic minimum’ in the final product because of the yeast 
cell proliferation under these conditions. The results presented in Table 2B (‘Maximising 
number of yeast cells by varying inoculum size of Turval B0399’) confirm this hypothesis. 
Even though 0.5% of inoculum gave the satisfactory number of yeast cells in the final 
product (2.8x105 /ml) we recommend 1% yeast inoculum as the best compromise between 
the high cell number and acceptable production cost (to compensate for the possible 
decline in the concentration of the probiotic organisms during storage of a probiotic). To 
question whether the number of probiotic bacteria declines below the proposed 
‘therapeutic minimum’ during refrigerated storage, we investigated the viability of 
probiotic species (yeast and bacteria) in yogurts stored in cold, 30 days after production.  
 
Table 3.  Microbiological analysis of the new generation fruit probiotic dairy beverage 
Probiotic culture 
















ABY-6 culture 39°C 7h 10% 8.1x106 - 
ABY-6 culture + 1% 
Turval 23.5°C 24h 10% 2.9x10
7 3.3x105
 
Table 4. Stability of physico-chemical characteristics of the new generation probiotic dairy 
beverages during long term (30 days), refrigerated storage














1st day after 
production 
30th day after 
production 
ABY-6 culture 39°C, 7h 4.77 32.0 4.58 35.0
ABY-6 culture + 1% 
Turval 23.5°C, 24h 4.72 33.0 4.60 35.0 
ABY-6 culture + 
0.5% Turval 23.5°C, 24h 4.73 32.0 4.60 35.0 
ABY-6 culture + 10% 
fruit paste 23.5°C, 24h 4.79 32.0 4.18 39.0 
ABY-6 culture + 1% 
Turval + 
10% fruit paste 
23.5°C, 24h 4.68 34.0 4.20 39.0 
 
The results are shown in Table 5 (‘Microbiological analysis of the new generation 
probiotic dairy beverages after 30 days of refrigerated storage’), showing 1 log decrease in 
the number of live probiotic bacteria after long-term storage and a lesser increase in the 
yeast count. Likewise, the viability of probiotic bacteria in products over a long shelf life at 
refrigeration temperature has been reported before to be unsatisfactory (Rybka and 
Kailasapathy, 1995, Lourens-Hattingh and Viljoen, 2001b). This is mainly due to a certain 
level of the ‘over-acidification’ during storage, which if it reaches pH values under 4.6 
may be harmful for probiotic species, particularly for bifidobacteria (Kailasapathy and 
Chin, 2000, Lourens-Hattingh and Viljoen, 2001b). As shown in Table 4 (‘Stability of 
physico-chemical characteristics of the new generation probiotic dairy beverages during 
long term (30 days), refrigerated storage’) the acidity of both classical probiotic yogurt 
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(ABY-6 species) and innovative, lactic yeast-based probiotic product (ABY-6 culture + 
Turval) decreased to pH 4.6 over the storage period. This could explain the slight decrease 
in the viability of probiotic bacteria, shown in Table 5, although the final count remained 
acceptable (above the therapeutic minimum). On the other hand, the ability to hydrolyse 
the residual lactose, utilisation of glucose and galactose produced by LAB and resistance 
to the low pH of Kluyveromyces cells are all plausible explanations for a minor increase in 
the yeast cell number over a long storage period (Table 5). However, this did not interfere 
with the sensorial characteristics of the product, which remained the same during the 
whole storage period.  
Table 5. Microbiological analysis of the new generation probiotic dairy beverages after 30 days of 
refrigerated storage 
Probiotic culture 








or Fruit paste 








ABY-6 39°C 7h / 1.3x106 /
ABY-6 + 1% Turval 23.5°C 24h / 1.3x106 6 x105
ABY-6 39°C 7h 10% fruit paste 2.7x106 /
ABY-6 + 1% Turval 23.5°C 24h 10% fruit paste 1.5x106 2.5x106
 
Production of the innovative fruit dairy probiotic beverage containing K.marxianus
B0399 
The 1% Turval B0399 inoculum was further used to produce an alternative, fruit-
containing, diary probiotic product by its co-inoculation with ABY-6 culture under optimal 
fermentation conditions (RT, 24h). As shown in Table 3 (‘Microbiological analysis of the 
new generation fruit probiotic dairy beverage’) the number of yeast cells in the product 
was satisfactory and similar to its concentration in the plane yogurt (>3x105/ml). Sensorial 
characteristics of this product were similar to the classical ‘fruit probiotic yogurt’ (ABY-6 
culture, 39°C fermentation temp.), while the number of probiotic bacteria in the Turval-
based product is slightly bigger than in the classical one, similarly to the plane probiotic 
products described previously (probably the result of the preferable fermentation 
conditions). In addition, we investigated the effect of commercial strawberry preparations 
on the viability of probiotic bacteria and probiotic yeast during storage (30 days) at 
refrigerated temperature. Again, we could observe the correlation between the post-storage 
over-acidification of fruit beverages (Table 4) and slightly decreased viability of probiotic 
bacteria (Table 5). While the number of probiotic bacteria in the fruit products slightly 
decreased over time but still remained satisfactory until the expiry date (30 days), the yeast 
cell viability showed exactly the opposite, increasing trend (Table 5). This 1 log increase in 
the yeast count is mainly due to the presence of proportions of sucrose and fructose derived 
from the fruit (Kailasapathy et al., 2008). Still, this did not interfere with the sensorial 
characteristics of the product, which remained the same in terms of taste and odour while a 
fairly recognisable decrease in acidity could be noticed, just like for the classical ‘fruit 
probiotic yogurt’ without lactic yeast.    
 
Conclusion  
The results obtained in this study demonstrated that fermented dairy products are great 
choice as food-carriers for the new generation probiotic yeast strain, K. marxianus B0399. 
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The sensory properties such as: appearance, texture, flavour and overall quality of 
probiotic dairy beverages containing Turval B0399 probiotic lactic yeast were comparable 
with standard 1.6% fat probiotic yogurt and they remained stable during the 30 day storage 
period. The pH values in all samples decreased during storage, where a bit higher 
dynamics could be observed for the fruit-containing yogurt and was not attributable to the 
presence of yeast. These innovative products are lacking yeasty flavour typical for dairy 
products containing Saccharomyces species (Lourens-Hattingh and Viljoen, 2001a), which 
may be explained by a distinct diapason of aroma compounds produced by K.marxianus 
strain (Fonseca, 2008). Even though it was not directly measured in this study, it is 
important to mention that K. marxianus B0399 produces very small amount of CO2 and 
ethanol at the end of 35-day shelf life of the commercially available, Italian branded, fruit 
based bio-yogurt EUFYR (Coop Italia, personal communication). This can be explained by 
strictly anaerobic metabolism of ethanol production of this yeast strain (Fonseca et al., 
2008), eliminating what was known to be the major constraints for incorporating another 
probiotic yeast strain, Saccharomyces boulardii into bio-yogurt (Lourens-Hattingh and 
Viljoen, 2001a).  
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